Financial Management and Assurance; Government Auditing Standards, 7090-7091 [2023-02124]
Download as PDF
7090
Federal Register / Vol. 88, No. 22 / Thursday, February 2, 2023 / Notices
Statutory
amount
Statutory provision
52 U.S.C. 30116(a)(1)(A) ........................................................................................................................................
52 U.S.C. 30116(a)(1)(B) ........................................................................................................................................
52 U.S.C. 30116(h) ..................................................................................................................................................
The limitation at 52 U.S.C.
30116(a)(1)(A) is to be in effect for the
two-year period beginning on the first
day following the date of the general
election in the preceding year and
ending on the date of the next regularly
scheduled election. 52 U.S.C.
30116(c)(1)(C); 11 CFR 110.1(b)(1)(ii).
Thus the $3,300 figure above is in effect
from November 9, 2022, to November 5,
2024. The limitations under 52 U.S.C.
30116(a)(1)(B) and 30116(h) shall be in
effect beginning January 1st of the oddnumbered year and ending on December
31st of the next even-numbered year. 11
CFR 110.1(c)(1)(ii). Thus the new
contribution limitations under 52 U.S.C.
30116(a)(1)(B) and 30116(h) are in effect
from January 1, 2023, to December 31,
2024. See 11 CFR 110.17(b)(1).
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The Act requires certain political
committees to disclose contributions
bundled by lobbyists/registrants and
lobbyist/registrant political action
committees once the contributions
exceed a specified threshold amount. 52
U.S.C. 30104(i)(1) and (i)(3)(A). The
Commission must adjust this threshold
amount annually to account for
inflation. 52 U.S.C. 30104(i)(3)(B). The
disclosure threshold is increased by
multiplying the $15,000 statutory
disclosure threshold by 1.45167, the
difference between the price index, as
certified to the Commission by the
Secretary of Labor, for the 12 months
preceding the beginning of the calendar
year and the price index for the base
period (calendar year 2006). See 52
U.S.C. 30104(i)(3) and 30116(c)(1)(B); 11
CFR 104.22(g). The resulting amount is
rounded to the nearest multiple of $100.
52 U.S.C. 30104(i)(3)(B) and
30116(c)(1)(B)(iii); 11 CFR 104.22(g)(4).
Based upon this formula ($15,000 ×
1.45167), the lobbyist bundling
disclosure threshold for calendar year
2023 is $21,800.
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than February 17, 2023.
A. Federal Reserve Bank of Atlanta
(Erien O. Terry, Assistant Vice
President) 1000 Peachtree Street NE,
Atlanta, Georgia 30309; Comments can
also be sent electronically to
Applications.Comments@atl.frb.org:
1. Mary Susan DeFoor, Ooltewah,
Tennessee; to acquire voting shares of
Millennium Bancshares, Inc., and
thereby indirectly acquire voting shares
of Millennium Bank, both of Ooltewah,
Tennessee.
Dated: January 27, 2023.
On behalf of the Commission,
Dara S. Lindenbaum,
Chair, Federal Election Commission.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–02135 Filed 2–1–23; 8:45 am]
[FR Doc. 2023–02190 Filed 2–1–23; 8:45 am]
BILLING CODE 6715–01–P
BILLING CODE P
Lobbyist Bundling Disclosure
Threshold for 2023
khammond on DSKJM1Z7X2PROD with NOTICES
FEDERAL RESERVE SYSTEM
VerDate Sep<11>2014
18:57 Feb 01, 2023
Jkt 259001
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
2023–2024
Limit
$2,000
25,000
35,000
$3,300
41,300
57,800
GOVERNMENT ACCOUNTABILITY
OFFICE
Financial Management and Assurance;
Government Auditing Standards
U.S. Government
Accountability Office.
AGENCY:
ACTION:
Notice of document availability.
On January 30, 2023, the U.S.
Government Accountability Office
(GAO) issued an exposure draft of
proposed revisions to Government
Auditing Standards (GAGAS), also
known as the Yellow Book. To help
ensure that the standards continue to
meet the needs of the government
community and the public it serves, the
Comptroller General of the United
States appointed the Advisory Council
on Government Auditing Standards to
review GAO’s proposed revisions of the
standards and consider other necessary
changes. The advisory council includes
experts from all levels of government,
the private sector, and academia. This
exposure draft includes the advisory
council’s input regarding the proposed
changes. We are requesting public
comments on the proposed revisions in
the 2023 exposure draft. All comments
received from the public will be
considered a matter of public record and
will be posted on the GAO website.
GAO first issued the standards in 1972.
The proposed changes in the exposure
draft update GAGAS to reflect major
developments in the accountability and
audit professions and emphasize
specific considerations applicable to the
government environment.
SUMMARY:
Comments will be accepted
through April 28, 2023.
DATES:
A copy of the exposure draft
(GAO–23–106303) can be obtained on
the GAO internet page at https://
www.gao.gov/yellowbook.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Cecil Davis at (202) 512–9362.
To ensure
that your comments are considered by
GAO and the advisory council in their
deliberations, please submit them by
April 28, 2023. Please send your
comments electronically to
YellowBookComments@gao.gov.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\02FEN1.SGM
02FEN1
Federal Register / Vol. 88, No. 22 / Thursday, February 2, 2023 / Notices
Authority: Public Law 67–13, 42 Stat.
20 (June 10, 1921).
James R. Dalkin,
Director, Financial Management and
Assurance, U.S. Government Accountability
Office.
[FR Doc. 2023–02124 Filed 2–1–23; 8:45 am]
In the
Federal Register of Monday, November
21, 2022 (87 FR 223), in FR Doc. 2022–
25315, the following correction is made:
On page 70835, in the table, the
entries for ANDAs 076434, 201832, and
203419 are removed.
SUPPLEMENTARY INFORMATION:
Dated: January 30, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
BILLING CODE 1610–02–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–02155 Filed 2–1–23; 8:45 am]
BILLING CODE 4164–01–P
Food and Drug Administration
[Docket No. FDA–2022–N–2826]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Allergan Sales LLC., et. al.; Withdrawal
of Approval of 10 Abbreviated New
Drug Applications; Correction
Food and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register on November 21, 2022. The
document announced the withdrawal of
approval (as of December 21, 2022) of 10
abbreviated new drug applications
(ANDAs) from multiple applicants. The
document indicated that FDA was
withdrawing approval of the following
ANDAs after receiving withdrawal
requests from Sunstar Americas, Inc.,
301 East Central Rd., Schaumburg, IL
60195: ANDA 076434, Chlorhexidine
Gluconate Solution, 0.12%; Sofgen
Pharmaceuticals, LLC, 21500 Biscayne
Blvd., Suite 600, Aventura, FL 33180:
ANDA 201832, Nimodipine Capsules,
30 milligrams (mg); and Indicus
Pharma, LLC, 2530 Meridian Parkway,
Durham, NC 27713: ANDA 203419,
Donepezil HCl Tablets, 23 mg. Before
FDA withdrew the approval of these
ANDAs, Sunstar Americas, Inc., Sofgen
Pharmaceuticals, LLC, and Indicus
Pharma, LLC informed FDA that they
did not want the approval of the ANDAs
withdrawn. Because Sunstar Americas,
Inc. timely requested that approval of
ANDA 076434 not be withdrawn,
Sofgen Pharmaceuticals, LLC timely
requested that the approval of ANDA
201832 not be withdrawn, and Indicus
Pharma, LLC timely requested that the
approval of ANDA 203419 not be
withdrawn, the approvals are still in
effect.
FOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1676,
Silver Spring, MD 20993–0002, 240–
402–6980, Martha.Nguyen@fda.hhs.gov.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:57 Feb 01, 2023
Jkt 259001
[Docket No. FDA–2014–N–0086]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Potential Tobacco
Product Violations Reporting Form
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the Potential
Tobacco Product Violations Reporting
Form.
SUMMARY:
Either electronic or written
comments on the collection of
information must be submitted by April
3, 2023.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
April 3, 2023. Comments received by
mail/hand delivery/courier (for written/
paper submissions) will be considered
timely if they are received on or before
that date.
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
7091
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2014–N–0086 for ‘‘Potential Tobacco
Product Violations Reporting Form.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
E:\FR\FM\02FEN1.SGM
02FEN1
Agencies
[Federal Register Volume 88, Number 22 (Thursday, February 2, 2023)]
[Notices]
[Pages 7090-7091]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-02124]
=======================================================================
-----------------------------------------------------------------------
GOVERNMENT ACCOUNTABILITY OFFICE
Financial Management and Assurance; Government Auditing Standards
AGENCY: U.S. Government Accountability Office.
ACTION: Notice of document availability.
-----------------------------------------------------------------------
SUMMARY: On January 30, 2023, the U.S. Government Accountability Office
(GAO) issued an exposure draft of proposed revisions to Government
Auditing Standards (GAGAS), also known as the Yellow Book. To help
ensure that the standards continue to meet the needs of the government
community and the public it serves, the Comptroller General of the
United States appointed the Advisory Council on Government Auditing
Standards to review GAO's proposed revisions of the standards and
consider other necessary changes. The advisory council includes experts
from all levels of government, the private sector, and academia. This
exposure draft includes the advisory council's input regarding the
proposed changes. We are requesting public comments on the proposed
revisions in the 2023 exposure draft. All comments received from the
public will be considered a matter of public record and will be posted
on the GAO website. GAO first issued the standards in 1972. The
proposed changes in the exposure draft update GAGAS to reflect major
developments in the accountability and audit professions and emphasize
specific considerations applicable to the government environment.
DATES: Comments will be accepted through April 28, 2023.
ADDRESSES: A copy of the exposure draft (GAO-23-106303) can be obtained
on the GAO internet page at https://www.gao.gov/yellowbook.
FOR FURTHER INFORMATION CONTACT: Cecil Davis at (202) 512-9362.
SUPPLEMENTARY INFORMATION: To ensure that your comments are considered
by GAO and the advisory council in their deliberations, please submit
them by April 28, 2023. Please send your comments electronically to
[email protected].
[[Page 7091]]
Authority: Public Law 67-13, 42 Stat. 20 (June 10, 1921).
James R. Dalkin,
Director, Financial Management and Assurance, U.S. Government
Accountability Office.
[FR Doc. 2023-02124 Filed 2-1-23; 8:45 am]
BILLING CODE 1610-02-P